Introduction {#tca12975-sec-0005}
============

Thoracotomy is one of the most painful surgical incisions. Postoperative pain reduces coughing and the mobilization of secretions, favoring respiratory complications, such as atelectasis and pneumonia. Thus, an effective analgesia is crucial to reduce postoperative morbidity and length of hospital stay (LOHS).

Thoracic epidural analgesia and thoracic paravertebral analgesia are the standard strategies for controlling post‐thoracotomy pain, but the difficulty of performing them in all patients and potential complications limit their use. Systemic administration of opioids is the simplest and most common method to provide analgesia, but it may be associated with several undesirable effects, such as respiratory depression, sedation, nausea, constipation, and vomiting.[1](#tca12975-bib-0001){ref-type="ref"} In recent years, preventive analgesia has been proposed as an alternative strategy for postoperative pain control. It is based on the concept of administering analgesic drugs before the occurrence of nociceptive input in order to prevent central sensitization.[2](#tca12975-bib-0002){ref-type="ref"} However, the effectiveness of pre‐emptive analgesia for controlling pain after thoracic surgery remains unclear.[3](#tca12975-bib-0003){ref-type="ref"} Post‐thoracotomy pain has a multifactorial genesis including surgical incision, intercostal nerve injury, pleural inflammation, and injury to pulmonary parenchyma and the diaphragm. Thus, a multimodal analgesia that intercepts the pain stimuli generated by different locations could be more effective than a single strategy targeting only one site along the pain pathway.

In the present study, we evaluated a new multimodal analgesia for controlling post‐thoracotomy pain as pre‐emptive analgesia of the skin using a lidocaine patch 5% associated with systemic administration of morphine.

Methods {#tca12975-sec-0006}
=======

Study design {#tca12975-sec-0007}
------------

This was a double‐blinded, placebo controlled, parallel‐group, prospective study conducted at the Thoracic Surgery Unit and Anesthesia and Intensive Care Unit of Second University of Naples, Naples, Italy, from January 2013 to May 2015. All consecutive patients undergoing anatomical resection by standard muscle‐sparing thoracotomy for treatment of non‐small cell lung cancer were randomly assigned to the lidocaine or placebo group in a 1:1 ratio. No changes to methods after trial commencement, such as type of randomization or eligibility criteria, were made.

The study design, planned according to the CONSORT‐SPIRIT guideline,[4](#tca12975-bib-0004){ref-type="ref"} was approved by the local ethics committee of our institution (approval code number: 436/2012) and was registered at [ClinicalTrial.gov](http://clinicaltrial.gov) (NCT02751619). The pros and cons of the lidocaine patch were explained to patients by the coordinator of the study and/or the staff participating in the study. Participants were informed that their participation was voluntary and that they might withdraw consent to participate at any time during the study without any consequences for their care. All patients gave written informed consent before entering into the study.

Participants {#tca12975-sec-0008}
------------

All consecutive patients aged \>18 years and undergoing anatomical resection by standard muscle‐sparing thoracotomy for non‐small cell lung cancer were eligible. Exclusion criteria included: (i) allergy to lidocaine; (ii) American Society of Anesthesiologists \>3; (iii) history of previous thoracic surgical procedures and/or of chronic pain or taking regular analgesics; (iv) pneumonectomy or concomitant decortication and/or chest wall injury or resection; (v) psychiatric illness; and (vi) participation to other studies. Demographic, functional, clinical and pathological data, LOHS, postoperative morbidity, and mortality were recorded for each patient.

Intervention {#tca12975-sec-0009}
------------

### Patch placement {#tca12975-sec-0010}

For patients assigned to the active group, a lidocaine patch 5% (Lidoderm; Endo Pharmaceuticals Inc., Malvern, PA, USA) measuring 10 × 14 cm and containing 700 mg of lidocaine was applied to cover the planned skin incision, marked with a pen by the surgeon. The patch was applied for 12 hours during the night, and removed for a subsequent 12 hours during the day. This process was repeated for three days before surgery. In the control group, a placebo patch, that was identical in appearance to the active patch, but did not contain lidocaine, was applied for the same amount of time. The pain service, surgical team, and patients were all blinded to the treatment group assigned.

### General anesthesia {#tca12975-sec-0011}

All patients underwent the same anesthetic protocol. All operations were performed in the early morning after removal of the patch. The general anesthesia was inducted with i.v. midazolam 0.05 mg/kg, i.v. fentanyl 1--1.4 μg/kg, i.v. propofol 2.5 mg/kg, and i.v. rocuronium bromide 0.6 mg/kg. The patient was maintained with desflurane 4--6%, sufentanil 0.5--1 μg/kg, and rocuronium bromide 0.6--0.8 mg/kg, based on heart rate and blood pressure stability. A selective ventilation was performed with a double‐lumen endobronchial tube in all cases, and no additional analgesics were administered during surgery.

### Surgical technique {#tca12975-sec-0012}

All patients had the same length of skin incision and a standard muscle‐sparing lateral thoracotomy. The latissimus dorsi muscle and the underlying serratus anterior muscle were spared, and the chest was entered over the top of the unresected and unfractured sixth rib. A standard Finocchietto chest retractor was then placed and slowly opened to avoid rib fracture. After completion of the appropriate anatomical lung resection, a single 28‐Fr chest tube was left in the pleural cavity. The same chest closure was performed for all patients in a standard manner using intra‐costal sutures.

### Postoperative pain control {#tca12975-sec-0013}

Patients were extubated in the operating room and transferred to the surgical ward. The postoperative analgesia was performed with intravenous morphine administered through Patient Controlled‐Analgesia (Automed 3300; AceMedical Co. Seoul, Korea) delivery. Morphine 1 mg was given for each request, and continuous infusion was at a rate of 1 mg/h. Both groups had a 10‐minute lockout period and a safe higher limit of 20 mg in 4 hours. If VAS scores exceeded 4/10 scores, rescue analgesia was intravenously administered according to a standardized institutional protocol for pain treatment until the pain was relieved to a level falling below a VAS score \<4. Patient‐controlled analgesia (PCA) was continued for up to two days, until patients could tolerate oral opioid medications and/or anti‐inflammatory analgesics. However, these medications were not considered in the analysis.

Primary end‐point {#tca12975-sec-0014}
-----------------

The primary end‐point was to evaluate whether lidocaine compared with a placebo was able to reduce the pain during the first 72 postoperative hours. The pain levels were measured using a 10‐score visual analog scale (VAS) ranging from 0 = absence of pain to 10 = maximal level of pain. The measurements were carried out at rest, and after coughing at 6, 12, 24, 36, 48, and 72 post‐operative hours.

Secondary end‐points {#tca12975-sec-0015}
--------------------

The secondary end‐points were to evaluate: (i) the frequency of PCA activation; (ii) total morphine consumption; (iii) recovery of post‐operatory respiratory function; (iv) any changes in sensory pathways; (v) LOHS; and (vi) postoperative morbidity.

### Frequency of PCA and morphine consumption {#tca12975-sec-0016}

The frequency of pushing the button of the PCA system (number/hour) and the total morphine consumption (the sum of additional i.v. morphine bolus infusions and the morphine delivered by the PCA system) were evaluated in the following postoperative intervals: 0--6 hours, 6--12 hours, 12--24 hours, 24--36 hours, and 36--48 hours.

### Respiratory function {#tca12975-sec-0017}

Bedside pulmonary functional test of flow expiratory volume in one second and forced vital capacity expressed as a percentage of the predicted value were measured using Spirolab III, Spirometer (Cosmed; Albano Laziale, Rome, Italy) before operation, at 72, 96, and 120 post‐operative hours, and at discharge. The best of three efforts was used for the analysis.

### Laser‐evoked potential tests {#tca12975-sec-0018}

Laser stimulation, delivered by neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser, was applied at the level of the thoracotomy scar, the main territory corresponding to the distribution of pain. Three seconds after each stimulus, a weak tone prompted the patient to rate the pain sensation on a 10‐score VAS scale with 4 denoting the pain threshold. Pain threshold intensity was determined by three series of stimuli ascending in steps of 30 mJ from below the sensation threshold to 90 mJ above the pain threshold and back again to below the sensation threshold. Thus, the pain threshold was the average of the six values at which the laser pulse was either first noted as a pinprick‐like pain sensation (VAS \>4) during an ascending series or as no longer painful (VAS \<4) during a descending series. For laser‐evoked potential (LEP) analysis, stimuli were given in blocks of 40 with randomized intensities (450 mJ and 600 mJ). The stimulus was supplied at irregular randomized intervals (between 10 and 20 s) to avoid the neurophysiological phenomenon called habituation that could compromise the signals recording. Electroencephalographic registration was made from four midline electrodes (FCs; Cz; CPz; and Pz) according to the international 10--20 system, using a standard electroencephalographic cap and Neuroscan software. We considered only the data from the vertex position (Cz), where pain‐related LEP are known to be maximal. Electro‐oculogram was recorded from supra‐ and infraorbital electrodes for offline artifact rejection. Room temperature was 22--23°C, and skin temperature was always \>30°C. The patients were instructed to keep their eyes open, to focus on a fixed point on the wall, and to avoid blinking. The resulting LEPs were evaluated for amplitude and latency differences between the vertex negativity (N2) appearing around 240 ms, and the following positivity (P2) appearing around 360 ms after stimulus onset. The LEPs were performed at 1, 3, and 6 months after operation, and in the same setting the level of pain was also measured with VAS.

Sample size {#tca12975-sec-0019}
-----------

We calculated our sample size based on the primary outcome measure as the VAS score. The power of the study was calculated using PASS 11 (NCSS, LLC. Kaysville, Utah, USA). For the parallel design, a sample size of 40 (40 per group) was calculated, assuming an intention to detect an effect size of 0.65 in the mean difference of the VAS score with 80% power, and a type I error rate of 0.05. In anticipation of missing data on the primary end‐point during the study period, we extended the number of patients to 90 before any comparative analysis.

Randomization {#tca12975-sec-0020}
-------------

Participants were randomly assigned with a 1:1 allocation to the lidocaine or placebo group by our research pharmacy, and it was based on computer‐generated codes. Each patient had an equal probability of being assigned to either the active treatment group or the placebo group. The details of the series were unknown to the investigators. The group assignments were kept in sealed envelopes, each bearing only the case number of the outside. After recruitment, the patients were given a case number, and 1 hour before placing the patch, the numbered envelope was opened and the card inside determined the group into which the patient would be placed. The lidocaine and placebo patch, labeled with the case number, were similar to keep all investigators blind to the patient\'s assigned group.

Statistical analysis {#tca12975-sec-0021}
--------------------

Data were summarized as the mean and standard deviation for normally distributed continuous variables; and absolute number and percentage for categorical variables, as appropriate. Statistical differences were evaluated using the χ^2^‐test for categorical variables, and *t*‐test for non‐categorical variables. Repeated measures analysis of variance ([anova]{.smallcaps} test) corrected with the Bonferroni post‐hoc test was used for comparison of variables measured at different time‐points of follow up.

All patients randomized were included in the analysis according to intention‐to‐treat analysis. For the primary end‐point (VAS score evaluation), we performed a conservative intention‐to‐treat analysis using all randomized patients. In that analysis, for the primary end‐points we assigned the worst possible observed score to missing data points for those assigned to the lidocaine group, and the best possible observed score to missing data for placebo patients. For the secondary outcomes, missing data were completed using the last observation carried forward analysis. The difference was considered significant for *P*‐values ≤0.05. MedCalc statistical software (version 12.3; Broekstraat 52, Mariakerke, Belgium) was used for the analysis.

Results {#tca12975-sec-0022}
=======

A total of 94 patients were eligible for the present study. Four patients were excluded because of allergy to lidocaine (*n* = 1), previous thoracic surgical procedure (*n* = 1), rib fracture during thoracotomy (*n* = 1), and refusing to perform the LEP test (*n* = 1). Thus, 90 out of 94 (96%) patients were randomly allocated into the lidocaine (*n* = 45) and placebo group (*n* = 45). One patient for each study group did not complete the follow‐up LEP tests, but they were included in the analysis according to study design. A flow chart of the study according to the CONSORT guidelines[4](#tca12975-bib-0004){ref-type="ref"} is reported in Figure [1](#tca12975-fig-0001){ref-type="fig"}. The demographic, clinical, and pathological data of the two study groups are summarized in Table [1](#tca12975-tbl-0001){ref-type="table"}.

![Flow chart of the study.](TCA-10-631-g001){#tca12975-fig-0001}

###### 

Characteristics of the study population

  Variables                        Total      Lidocaine group   Placebo group   *P*‐value
  ----------------------------- ------------ ----------------- --------------- -----------
  No. patients                       90             45               45            ---
  Male                            70 (77%)       31 (69%)         39 (87%)        0.04
  Age (years)                    62.3 ± 7.9      63 ± 4.9        60.2 ± 11.3      0.69
  Charlson Comorbidity Index     1.3 ± 4.2       1.3 ± 1.8        1.3 ± 2.7       0.89
  ASA classification                                                              0.33
  ASA 1                           79 (88%)       41 (91%)         38 (84%)     
  ASA 2                           10 (11%)        4 (9%)           6 (14%)     
  ASA 3                            1 (1%)            0             1 (2%)      
  Clinical stage                                                               
  Ia                             15 (16.5%)       6 (13%)          9 (20%)        0.39
  Ib                              25 (28%)       16 (36%)          9 (20%)        0.10
  IIa                             35 (39%)       16 (36%)         19 (42%)        0.51
  IIb                            15(16.5%)        7 (15%)          8 (18%)        0.77
  FEV1%                          91 ± 16.3       91 ± 2.9          91 ± 11        0.79
  FVC%                            90 ± 8.5       90 ± 3.7         90 ± 6.9        0.91
  Type of resection                                                            
  Lobectomy                       89 (99%)       44 (98%)         45 (100%)       0.31
  Bilobectomy                      1 (1%)         1 (2%)              0        
  Histology                                                                    
  Adenocarcinoma                  50 (55%)       29 (64%)         21 (47%)        0.09
  Squamous cell carcinoma         35 (39%)       12 (27%)         23 (51%)        0.01
  Large cell carcinoma             5 (6%)         4 (9%)           1 (2%)      
  Pathological stage                                                           
  Ia                              14 (16%)        6 (13%)          8 (18%)        0.56
  Ib                              22 (24%)       15 (33%)          7 (16%)        0.05
  IIa                             33 (37%)       15 (33%)         18 (40%)        0.51
  IIb                             19 (21%)        8 (19%)         11 (24%)        0.44
  IIIA                             2 (2%)         1 (2%)           1 (2%)          1.0
  Operative time                 186 ± 24.5      188 ± 31        184 ± 19.4       0.87
  Chest drain length (days)      5.8 ± 2.6       5.7 ± 2.8        5.9 ± 3.1       0.91
  Hospital stay (days)            7 ± 4.6        6.9 ± 2.1        7.1 ± 1.9       0.93
  Postoperative complications                                                  
  Atelectasis                      7 (8%)         2 (4%)           5 (11%)        0.24
  Air leaks                        3 (3%)         2 (4%)           1 (2%)         0.55
  Atrial fibrillation              1 (1%)           ---            1 (2%)         0.31

Data are expressed as mean ± standard deviations and/or as percentages. *P*‐value was calculated using the χ^2^‐test and *t*‐test. ASA, American Society of Anesthesiologists; FEV1%, forced expiratory volume in one second; FVC, forced vital capacity.

Primary end‐point {#tca12975-sec-0023}
-----------------

The results of the VAS scores are reported in Table [2](#tca12975-tbl-0002){ref-type="table"} and Figure [2](#tca12975-fig-0002){ref-type="fig"}. The [anova]{.smallcaps} test showed that lidocaine compared with placebo had significantly lower VAS scores at rest (*P* = 0.013; Fig [2](#tca12975-fig-0002){ref-type="fig"}a). However, considering *P*‐values adjusted for comparison at multiple times by the Bonferroni post‐hoc test, we found no significant difference between the two study groups at 6 post‐operative hours (*P* = 0.1) and at 72 post‐operative hours (*P* = 0.2).

###### 

Comparison of two study groups

  Variables              Time          Lidocaine group   Placebo group  *P* [\*](#tca12975-note-0002){ref-type="fn"}    *P* [\*\*](#tca12975-note-0003){ref-type="fn"}
  ---------------------- ------------ ----------------- --------------- ---------------------------------------------- ------------------------------------------------
  VAS at rest            6 POHs           3.8 ± 0.7        4.3 ± 0.6    0.18                                                                0.013
  12 POHs                3.7 ± 0.4        4.4 ± 0.5          0.01                                                      
  24 POHs                3.0 ± 0.4        3.8 ± 0.3          0.003                                                     
  48 POHs                2.4 ± 0.6        3.0 ± 0.4          0.01                                                      
  72 POHs                1.6 ± 0.6        2.0 ± 0.5          0.25                                                      
  VAS after coughing     6 POHs           4.8 ± 0.7        5.3 ± 0.6    0.15                                                                0.015
  12 POHs                4.7 ± 0.4        5.4 ± 0.5          0.01                                                      
  24 POHs                4.0 ± 0.4        4.8 ± 0.2          0.003                                                     
  48 POHs                3.4 ± 0.6        4.0 ± 0.4          0.01                                                      
  72 POHs                2.6 ± 0.6        3.0 ± 0.5          0.37                                                      
  Frequency of PCA       6 POHs           4.3 ± 0.9        5.2 ± 0.7    0.03                                                                0.001
  6--12 POHs             3.3 ± 0.6        6.4 ± 0.5          0.004                                                     
  12--24 POHs            2.2 ± 0.9        4.3 ± 0.8          0.001                                                     
  24--36 POHs            1.5 ± 0.5        3.2 ± 0.7          0.005                                                     
  36--48 POHs            0.5 ± 0.2        0.7 ± 0.3          0.04                                                      
  Morphine consumption   6 POHs           20.3 ± 2        24.4. ± 4.1   0.02                                                                0.001
  6--12 POHs             19 ± 2.1        22.4 ± 3.2          0.003                                                     
  12--24 POHs            18 ± 2.4        21.7 ± 2.1          0.002                                                     
  24--36 POHs            12 ± 1.5         16 ± 1.7           0.001                                                     
  36--48 POHs            2.1 ± 0.9        3.5 ± 0.8          0.03                                                      
  FEV1%                  Baseline        89.9 ± 9.7       96.4 ± 6.4    0.85                                                                0.025
  72 POHs                77.7 ± 8.8      70.1 ± 4.7          0.023                                                     
  96 POHs                79.5 ± 7.8      70.4 ± 4.8          0.021                                                     
  120 POHs               79.8 ± 7.4      71.7 ± 4.2          0.025                                                     
  Discharge              81.5 ± 7.8      72.4 ± 4.8          0.024                                                     
  FVC%                   Baseline        94.9 ± 6.6       97.4 ± 6.4    0.92                                                                0.037
  72 POHs                82.8 ± 7.4      74.7 ± 4.2          0.029                                                     
  96 POHs                82.7 ± 6.9      76.2 ± 6.2          0.035                                                     
  120 POHs               85 ± 4.9        81.8 ± 8.5          0.038                                                     
  Discharge              87 ± 4.9        83.8 ± 8.2          0.040                                                     
  P2 amplitude           Baseline         9.6 ± 0.7        11 ± 1.7     0.27                                                                0.001
  1 POM                  8.4 ± 0.9        3.9 ± 0.6         0.0003                                                     
  3 POMs                 8.7 ± 0.8        4.8 ± 0.9         0.0004                                                     
  6 POMs                 9.7 ± 0.7        5.6 ± 0.3          0.001                                                     
  P2 latency             Baseline         455 ± 8.3        441 ± 7.9    0.071                                                               0.025
  1 POM                  465 ± 8.3        495 ± 5.5          0.015                                                     
  3 POMs                 463 ± 8.6        485 ± 4.3          0.016                                                     
  6 POMs                 454 ± 8.7        482 ± 5.3          0.023                                                     
  N2 amplitude           Baseline         −28 ± 1.3        −27 ± 1.9    0.67                                                                0.035
  1 POM                  −31 ± 1.9        −50 ± 3.9          0.024                                                     
  3 POMs                 −30 ± 1.6        −49 ± 1.7          0.025                                                     
  6 POMs                 −28 ± 5.9        −41 ± 2.9          0.027                                                     
  N2 latency             Baseline         262 ± 8.7        257 ± 5.4    0.73                                                                0.023
  1 POM                  271 ± 7.3        296 ± 8.9          0.023                                                     
  3 POMs                 265 ± 5.8        293 ± 3.8          0.027                                                     
  6 POMs                 263 ± 8.9        289 ± 4.3          0.025                                                     

Bonferroni post‐hoc test

[anova]{.smallcaps} test.

POH, postoperative hour; POM, postoperative month.

![The lidocaine group compared with the placebo group had significantly lower visual analog scale (VAS) scores (**a**) at rest (*P* = 0.013) and (**b**) after coughing (*P* = 0.015). (![](TCA-10-631-g006.jpg "image")) Lidocaine and (![](TCA-10-631-g007.jpg "image")) placebo.](TCA-10-631-g002){#tca12975-fig-0002}

Similar results were found for VAS scores after coughing (Fig [2](#tca12975-fig-0002){ref-type="fig"}b). They were found to be significantly lower in the lidocaine group than in the placebo group (*P* = 0.015; [anova]{.smallcaps} test), but a post‐hoc test showed no significant difference between the two study groups at 6 (*P* = 0.1) and at 72 post‐operative hours (*P* = 0.3).

Secondary end‐points {#tca12975-sec-0024}
--------------------

### The frequency of PCA and morphine consumption {#tca12975-sec-0025}

The results are shown in Table [2](#tca12975-tbl-0002){ref-type="table"} and in Figure [3](#tca12975-fig-0003){ref-type="fig"}. The administration frequency of PCA (*P* = 0.001; Fig [3](#tca12975-fig-0003){ref-type="fig"}a) and the total administration of morphine (*P* = 0.001, Fig [3](#tca12975-fig-0003){ref-type="fig"}b) was higher in the placebo group compared with the lidocaine group for all follow‐up time points.

![(**a**) The administration frequency of patient‐controlled analgesia (PCA) expressed as number/hour (*P* = 0.001) and (**b**) the total consumption of morphine expressed as mg (*P* = 0.001) were higher in the placebo group compared with the lidocaine group. (![](TCA-10-631-g008.jpg "image")) Lidocaine and (![](TCA-10-631-g009.jpg "image")) placebo.](TCA-10-631-g003){#tca12975-fig-0003}

### Respiratory function {#tca12975-sec-0026}

The results are summarized in Table [2](#tca12975-tbl-0002){ref-type="table"} and in Figure [4](#tca12975-fig-0004){ref-type="fig"}. The recovery of flow expiratory volume in one second (*P* = 0.025; Fig [4](#tca12975-fig-0004){ref-type="fig"}a) and the forced vital capacity (*P* = 0.037, Fig [4](#tca12975-fig-0004){ref-type="fig"}b) was faster in the lidocaine group than in the placebo group.

![The recovery of (**a**) forced expiratory volume in one second (FEV1%; *P* = 0.025) and of (**b**) forced vital capacity (FVC%; *P* = 0.037) was faster in the lidocaine group than in the placebo group. (![](TCA-10-631-g010.jpg "image")) Lidocaine and (![](TCA-10-631-g011.jpg "image")) placebo. POH, postoperative hour; POM, postoperative month.](TCA-10-631-g004){#tca12975-fig-0004}

### LEP tests {#tca12975-sec-0027}

As reported in Table [3](#tca12975-tbl-0003){ref-type="table"}, in the lidocaine group, no significant difference was found between baseline and post‐operative values of N2 and P2 LEP. In contrast, in the placebo group, a significant reduction of N2 and P2 in amplitude, and a significant increase of N2 and P2 in latency were observed. The comparison between the two study groups (Table [2](#tca12975-tbl-0002){ref-type="table"}) showed that the placebo group compared with the lidocaine group had a significant reduction of N2 (*P* = 0.001; Fig [5](#tca12975-fig-0005){ref-type="fig"}a) and of P2 (*P* = 0.035, Fig [5](#tca12975-fig-0005){ref-type="fig"}b) in amplitude, and a significant increase of N2 (*P* = 0.023; Fig [5](#tca12975-fig-0005){ref-type="fig"}c) and of P2 (*P* = 0.025; Fig [5](#tca12975-fig-0005){ref-type="fig"}d) in latency.

###### 

P2 and N2 value of study groups

                                             Postoperative                          
  -------------- -------------- ----------- --------------- ----------- ----------- --------
  Lidocaine      P2 amplitude    9.6 ± 0.7     8.4 ± 0.9     8.7 ± 0.8   9.7 ± 0.7  0.8
  P2 latency     455 ± 8.3       465 ± 8.3     463 ± 8.6     454 ± 8.7      0.2     
  N2 amplitude   −28 ± 1.3       −31 ± 1.9     −30 ± 1.6     −28 ± 5.9      0.3     
  N2 latency     262 ± 8.7       271 ± 7.3     265 ± 5.8     263 ± 8.9      0.8     
  Placebo        P2 amplitude    11 ± 1.7      3.9 ± 0.6     4.8 ± 0.9   5.6 ± 0.3  0.0001
  P2 latency     441 ± 7.9       495 ± 5.5     485 ± 4.3     482 ± 5.3    0.0001    
  N2 amplitude   −27 ± 1.9       −50 ± 3.9     −49 ± 1.7     −41 ± 2.9    0.0004    
  N2 latency     257 ± 5.4       296 ± 8.9     293 ± 3.8     289 ± 4.3    0.0002    

The *P*‐value was calculated with [anova]{.smallcaps} test.

![The placebo group compared with the lidocaine group had a significantly lower value in the amplitude of (**a**) N2 (*P* = 0.001) and of (**b**) P2 (*P* = 0.035), and a higher value in the latency of (**c**) N2 (*P* = 0.023) and of (**d**) P2 (*P* = 0.025). (![](TCA-10-631-g012.jpg "image")) Lidocaine and (![](TCA-10-631-g013.jpg "image")) placebo.](TCA-10-631-g005){#tca12975-fig-0005}

### Other data {#tca12975-sec-0028}

No significant difference was found regarding operative time (*P* = 0.87), length of chest drainage (*P* = 0.93) and LOHS (*P* = 0.93), and postoperative complications (*P* = 0.33). In addition, the use of the lidocaine patch was not associated with specific side‐effects (Table [1](#tca12975-tbl-0001){ref-type="table"}).

Discussion {#tca12975-sec-0029}
==========

In the past decade, a growing number of diagnostic and curative procedures have been performed using video‐assisted thoracoscopic surgery,[5](#tca12975-bib-0005){ref-type="ref"}, [6](#tca12975-bib-0006){ref-type="ref"} but thoracotomy still remains the most common incision among thoracic surgeons, and the preferred approach in many centers for resecting advanced stage non‐small cell lung cancer or for performing complex procedures, such as broncho‐vascular resection.[7](#tca12975-bib-0007){ref-type="ref"}

Pre‐emptive analgesia is based on the intuitive idea that if pain is treated before the injury occurs, the nociceptive system will perceive less pain than if analgesia is given after the injury has already occurred.[8](#tca12975-bib-0008){ref-type="ref"}, [9](#tca12975-bib-0009){ref-type="ref"} The injection of lidocaine before surgical incision showed significant pain reduction after video‐assisted thoracoscopic surgery sympathectomy,[10](#tca12975-bib-0010){ref-type="ref"}, [11](#tca12975-bib-0011){ref-type="ref"} but Cerfolio *et al.* did not find any benefits in patients undergoing thoracotomy.[12](#tca12975-bib-0012){ref-type="ref"} In theory, the pre‐emptive effect of lidocaine controlled the pain stimuli generated from the surgical incision, but not those caused by intercostal nerve injury or visceral components, such as the lung, pleura, and diaphragm, during the surgical maneuvers. To overcome this limit, in the present study, we planned a new strategy, not reported before, as the association between the pre‐emptive skin analgesia with a lidocaine patch and the PCA morphine analgesia. The clinical hypothesis was that this multimodal analgesia, acting at different sites of pain pathways, such as thoracotomy (through the lidocaine patch) and the cortex (through the morphine), could better control thoracotomy pain compared with the administration of morphine alone.

Our results showed a better control of postoperative pain, a significant reduction of the frequency of PCA activation and of morphine consumption, and a faster recovery of respiratory function in the active group compared with the placebo group. The analgesic effect of the lidocaine patch was mainly due to the pre‐emptive block of noxious input from the skin incision.[13](#tca12975-bib-0013){ref-type="ref"}, [14](#tca12975-bib-0014){ref-type="ref"}, [15](#tca12975-bib-0015){ref-type="ref"}, [16](#tca12975-bib-0016){ref-type="ref"} In fact, lidocaine was absorbed by painful fibers of the skin, and, through the block of the sodium channels of the neuronal membrane, prevented the generation and conduction of action potential from the periphery (site of incision) to the cortex.[13](#tca12975-bib-0013){ref-type="ref"}, [14](#tca12975-bib-0014){ref-type="ref"}, [15](#tca12975-bib-0015){ref-type="ref"}, [16](#tca12975-bib-0016){ref-type="ref"} The block of the afferent pain transmission resulted in a reduction of pain perception. An additional mechanism was the reduction of the acute phase of inflammatory reactions, as lidocaine inhibited the activation of neutrophil and reduced the local release of cytokines.[17](#tca12975-bib-0017){ref-type="ref"}, [18](#tca12975-bib-0018){ref-type="ref"}, [19](#tca12975-bib-0019){ref-type="ref"} Furthermore, we found a significant reduction of VAS score not only at rest, but also after coughing, showing the effectiveness of the lidocaine patch to control pain also at a deeper level than surgical incision. Our results were confirmed by previous studies that found that the lidocaine patch provided good analgesic relief and an improvement of pulmonary functional tests in patients with rib fractures.[20](#tca12975-bib-0020){ref-type="ref"}, [21](#tca12975-bib-0021){ref-type="ref"} Lidocaine\'s half‐life was 1.5--2 hours, but we observed a significant reduction of pain for a longer time, supporting the preventive action of our analgesic treatment. As a matter of fact, preventive analgesia is shown when postoperative pain and/or analgesic use are reduced beyond the duration of action of the target drug; that is, approximately 5.5 half‐lives of the target drug.[3](#tca12975-bib-0003){ref-type="ref"} In the present study, post‐hoc tests showed a significant reduction of VAS score up to 48 hours after the operation. Thus, the pre‐emptive inhibition of the sensitization of central nociceptive pathways through the blockage of peripheral nociceptive pathways rather than the simple local effect of lidocaine explained the analgesic effects. Conversely, despite a positive trend, pre‐emptive analgesia did not bring about any significant benefits within the first six postoperative hours (*P* = 0.1). In theory, the effects of general anesthesia on pain were still present during the early postoperative hours and thus masked the analgesic effect of lidocaine.

In the placebo group, we found significant changes, such as a reduction in amplitude and increase in latency of N2‐P2 components compared with the pre‐operative values, whereas the lidocaine group showed similar postoperative N2‐P2 values compared with baseline. However, the VAS values between the two groups were similar during the same follow‐up times. It means that LEPs were not associated with subjective pain perception, but they reflected the state of the sensory pathway. Similar results were obtained in tooth pulp stimulation, where evoked potential became reduced in amplitude while pain ratings were unchanged.[22](#tca12975-bib-0022){ref-type="ref"} In theory, the lack of sensitization of nociceptive peripheral pathways due to the pre‐emptive effect of lidocaine could explain the normal LEPs observed in the active group. In contrast, in the placebo group, the nerve sensitization could alter the integrity and the function of small painful fibers, such as A‐delta and C fibers, with consequent LEPs changes. In peripheral neuropathies, where the small fiber disease shows a characteristic predominance of loss in autonomous peripheral nerve function, LEP may be absent or attenuated in amplitude, indicating impaired function of both A‐delta and C‐fibers. In patients with carpal tunnel syndrome, LEP amplitude was reduced due to the stimulation of the third finger.[23](#tca12975-bib-0023){ref-type="ref"} Agostino *et al.* investigated LEPs in 45 diabetes patients with various degrees of peripheral nerve damage, and reported that the most frequent abnormalities were absent or decreased amplitude LEPs, as expected in axonopathies.[24](#tca12975-bib-0024){ref-type="ref"} However, the short follow‐up period of our study was unable to show whether LEP alteration could predispose to post‐thoracotomy syndrome in the placebo group.

The use of the lidocaine patch was safe and no collateral effect was observed in the active group. Each patch contains 700 mg lidocaine and a total of 3 ± 2% of the dose was absorbed. In accordance with previous studies, the patch was used with an interval of 12 hours per three consecutive days in order to avoid the habituation of the nerve to lidocaine effects, and to reduce the risk of toxic effects.[11](#tca12975-bib-0011){ref-type="ref"}, [12](#tca12975-bib-0012){ref-type="ref"}, [13](#tca12975-bib-0013){ref-type="ref"}, [14](#tca12975-bib-0014){ref-type="ref"} The blood levels of the lidocaine 5% patch were minimal when applied at a maximum dose of three patches each day for 12 hours, and also when four patches each day were applied for 18 hours. Pharmacological studies found that the systemic circulation reached only one out of 10 of the concentration required in the treatment of cardiac arrhythmias.[13](#tca12975-bib-0013){ref-type="ref"}, [14](#tca12975-bib-0014){ref-type="ref"}, [15](#tca12975-bib-0015){ref-type="ref"}, [16](#tca12975-bib-0016){ref-type="ref"}

Our results are in contrast with those of Cerfolio *et al.*, who did not find significant benefits associated with pre‐emptive skin analgesia for controlling postoperative pain.[12](#tca12975-bib-0012){ref-type="ref"} Several reasons may explain the different results. We believe that the main and most important difference was the procedure adopted for obtaining pre‐emptive skin analgesia. In contrast to the traditional percutaneous injection of lidocaine, as that performed by Cerfolio *et al.*, the lidocaine patch was designed to deliver the same concentration of anesthetic, thus facilitating a uniform pre‐analgesia effect within all parts of the surgical incision.[12](#tca12975-bib-0012){ref-type="ref"} Again, Cerfolio *et al.* injected lidocaine 5 minutes before incision, whereas in the present study the skin was pre‐emptively anesthetized three days before incision.[12](#tca12975-bib-0012){ref-type="ref"} In theory, the longer exposure to lidocaine could perpetuate the complete block of peripheral pain pathways, and thus maximize the pre‐emptive effect of lidocaine. In addition, the different thoracotomy performed (postero‐latheral in Cerfolio\'s study[12](#tca12975-bib-0012){ref-type="ref"} vs. lateral with muscle sparing in the present study), postoperative analgesia administered (epidural in Cerfolio\'s study[12](#tca12975-bib-0012){ref-type="ref"} vs. systemic morphine analgesia in the present study), and measure of pain (McGill model in Cerfolio\'s study[12](#tca12975-bib-0012){ref-type="ref"} vs. VAS scale in the present study) could also explain the differences in the results.

Our data should be considered with caution due to the following limitations: (i) all patients received a postoperative regimen based on i.v. morphine that may be inadequate for controlling pain and thus it makes it easier to find differences between the two study groups; (ii) the pain was measured with VAS, which can be influenced by many variables in contrast to more sophisticated means of quantifying pain, such as the McGill pain questionnaire; (iii) only one patch for 12 hours was used in all patients without considering the variations in patients' skin thickness that could affect the diffusion of lidocaine through the tissues. Ideally, in patients with greater skin thickness, more than one patch could be used due to the low rate of lidocaine diffusion.

In conclusion, pre‐emptive skin analgesia using a lidocaine patch is a safe, quick, and simple procedure for controlling post‐thoracotomy pain. It improves pain relief while reducing morphine requirements and morphine‐related adverse effects. Thus, it could be considered an adjuvant modality to systemic morphine analgesia, especially for patients where epidural and/or paravertebral block analgesia are contraindicated. Obviously, larger studies are required to confirm our results before this strategy can be widely recommended in thoracic surgery.
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